HDAC6 and Ovarian Cancer

被引:27
|
作者
Haakenson, Joshua [1 ]
Zhang, Xiaohong [1 ,2 ]
机构
[1] Univ S Florida, Morsani Coll Med, Dept Pathol & Cell Biol, Tampa, FL 33612 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Program Mol Oncol, Tampa, FL 33612 USA
关键词
HDAC6; ovarian cancer; cancer-related signaling pathways; inhibitors; cell stress response; motility; oncogenesis; histone deacetylase; HISTONE DEACETYLASE 6; REGULATES AGGRESOME FORMATION; 2 CATALYTIC DOMAINS; CELL-MIGRATION; MICROTUBULE ACETYLATION; GLUCOCORTICOID-RECEPTOR; STRESS GRANULES; PROTEIN; TUBULIN; INHIBITORS;
D O I
10.3390/ijms14059514
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The special class IIb histone deacetylase, HDAC6, plays a prominent role in many cellular processes related to cancer, including oncogenesis, the cell stress response, motility, and myriad signaling pathways. Many of the lessons learned from other cancers can be applied to ovarian cancer as well. HDAC6 interacts with diverse proteins such as HSP90, cortactin, tubulin, dynein, p300, Bax, and GRK2 in both the nucleus and cytoplasm to carry out these cancerous functions. Not all pro-cancer interactions of HDAC6 involve deacetylation. The idea of using HDAC6 as a target for cancer treatment continues to expand in recent years, and more potent and specific HDAC6 inhibitors are required to effectively down-regulate the tumor-prone cell signaling pathways responsible for ovarian cancer.
引用
收藏
页码:9514 / 9535
页数:22
相关论文
共 50 条
  • [1] The Role of HDAC6 in Cancer
    Aldana-Masangkay, Grace I.
    Sakamoto, Kathleen M.
    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2011,
  • [2] A key HDAC6 dependency of ARID1A-mutated ovarian cancer
    Lucia Altucci
    Nature Cell Biology, 2017, 19 : 889 - 890
  • [3] A key HDAC6 dependency of ARID1A-mutated ovarian cancer
    Altucci, Lucia
    NATURE CELL BIOLOGY, 2017, 19 (08) : 889 - 890
  • [4] HDAC6: A unique HDAC family member as a cancer target
    Sumeet Kaur
    Prerna Rajoria
    Madhu Chopra
    Cellular Oncology, 2022, 45 : 779 - 829
  • [5] HDAC6: A unique HDAC family member as a cancer target
    Kaur, Sumeet
    Rajoria, Prerna
    Chopra, Madhu
    CELLULAR ONCOLOGY, 2022, 45 (05) : 779 - 829
  • [6] SET7 interacts with HDAC6 and suppresses the development of colon cancer through inactivation of HDAC6
    Zhang, Shi-Lan
    Du, Xiao
    Tan, Lin-Na
    Deng, Fei-Hong
    Zhou, Bing-Yi
    Zhou, He-Jun
    Zhu, Hong-Yi
    Chu, Yi
    Liu, De-Liang
    Tan, Yu-Yong
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (02): : 602 - 611
  • [7] Design and synthesis of novel HDAC6 inhibitor dimer as HDAC6 degrader for cancer treatment by palladium catalysed dimerisation
    Lin, Ching
    Hsu, Jui-Ling
    Hsu, Yu-Tung
    Fan, Kuo-Chen
    Wu, Sian-Siou
    Lin, Miao-Hsia
    Guh, Jih-Hwa
    Yu, Chao-Wu
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2025, 40 (01)
  • [8] HDAC6 and DNMT inhibition affect immunogenicity of ovarian cancer cells: A rationale for combining epigenetic and immune therapy in ovarian cancer
    Srivastava, Aneil P.
    Moufarrij, Sara M.
    Hadley, Melissa
    Chisholm, Sarah
    Lopez-Acevedo, Micael
    Villagra, Alejandro
    Chiappinelli, Katherine B.
    CANCER RESEARCH, 2018, 78 (13)
  • [9] HDAC6 & DNMT Inhibition Alter Immunogenicity of Ovarian Cancer Cells: A Rationale for Combination Therapy
    Moufarrij, Sara Maria
    Srivastava, Aneil
    Hadley, Melissa
    Lopez, Micael
    Villagra, Alejandro
    OBSTETRICS AND GYNECOLOGY, 2019, 133 : 30S - 30S
  • [10] HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells
    Ali, Ahlam
    Zhang, Fengyu
    Maguire, Aaron
    Byrne, Tara
    Weiner-Gorzel, Karolina
    Bridgett, Stephen
    O'Toole, Sharon
    O'Leary, John
    Beggan, Caitlin
    Fitzpatrick, Patricia
    McCann, Amanda
    Furlong, Fiona
    CANCERS, 2020, 12 (12) : 1 - 20